Anjali Joshi is an accomplished technology executive and electrical engineer who has held important leadership roles in several high-growth companies. Joshi is an eleven year veteran at Google, Inc. where she served as Vice President for Product Management. During her tenure at Google she led teams on marquee Google products such as Search and adapted cutting edge technologies to solve major healthcare issues in underserved populations. Ms. Joshi received her B.Tech. in Electrical Engineering from IIT Kanpur in 1981. Following it, she went to the USA and obtained her master’s degree in Computer Engineering from the State University of New York and another master’s in Engineering Management from Stanford University.
When: January 28, 1999
“Winning Against Odds: Crossing Barriers in Drug Delivery Area”
Dr Dinesh Patel
Founder and CEO / President, Theratech Inc.
Stephanie Marrus is an entrepreneurial business executive whose latest accomplishment is starting companies from science and medical technologies for a University of California campus. She has built the Entrepreneurship Center at UCSF into a vibrant ecosystem for entrepreneurship and innovation, preparing high impact science and technology startups for angel and venture capital investment. Prior to joining UCSF, she held various positions in business including CEO, COO, VP Business Development, VP Corporate Development, head of Strategy and Marketing for public and private venture capital- backed companies in science and technology. She is a strong innovative leader, charismatic and energetic. A problem solver and creative thinker, she finds a path to accomplish goals.
Dr. Rajen Dalal, Ph.D. served as Director of Soleno Therapeutics, Inc. since April 14, 2016 until January 1, 2019. He served as the Chief Executive Officer and Director of Aviir Inc. from October 2006 to 2008. Dr. Dalal is an industry consultant and a seasoned executive. He served as the Chief Executive Officer and President of PharmaJet, Inc. He served as the President and Chief Executive Officer of Guava Technologies Inc. from 2002 to February 2005. From 2011 to 2016, he served as the Chief Executive Officer of WJR Biotech, Inc. He was managing director of Synergenics LLC. Prior to joining Guava in 2002, he served as Vice President of Chiron, Corp. and served as its President of Blood Testing division from 1998 to 2002. Mr. Dalal also served as Vice President of Corporate Development of Chiron from 1992 to 1998. Prior to joining Chiron in 1991, he was a leader of McKinsey & Company’s pharmaceuticals and technology management groups. Dr. Dalal has been a Member of Advisory Board at SpinX Technologies SA since July 2007. He has been an Independent Director of Capnia, Inc. since April 15, 2016. He served as a Director of WJR Biotech, Inc. from 2006 to 2015. He served as a Director at Sagres Discovery, Inc.; Guava Technologies, Inc., and Vermillion, Inc. (also known as Ciphergen Biosystems Inc.) from 2003 to March 27, 2009. He has served on the board of Singapore based A-Bio Pharma and Dx Assays from 2008 to 2010. In 2007, he co-founded the San Francisco Bay Area Outward Bound and is an Emeritus Director. Dr. Dalal received a bachelor’s degree in chemistry and from St. Xavier’s College, the University of Bombay, a master’s degree in biochemical engineering from the Massachusetts Institute of Technology and an MBA from the University of Chicago. Dr. Dalal has served as the CEO and board member of several medical device companies including from 2011-2015, ReLIA Diagnostic Systems, Inc.
Ted Driscoll is Managing Director at a new venture fund, DigitalDx Ventures, whose focus is on Diagnostics in a Big-Data and Personalized Medicine World. Previously he was a Partner at Decheng Capital, and a Partner at Claremont Creek Ventures leading Digital Healthcare. He led the first investment in Natera (IPOed 2015), AssureX (acquired by Myriad Genetics for $410M) and GeneWeave (acquired by Roche for $425M). Prior to entering venture capital, he was an early leader/founder of five startups. His first startup, International Imaging Systems, built the first Digital Subtractive Angiography machines. He then led the team at Identix that pioneered the first digital fingerprint recognition, now used in the iPhone. Identix IPOed in 1984. He then joined Diasonics where he led the team that created the world’s first MRI scanners. He was then named Division President of a spinoff from Diasonics named Focus Surgery that pioneered noninvasive HIFU ablation surgery. This company IPOed in 1992. His last startup was Be Here Technologies, a 360degree imaging company, which was purchased by and incorporated into Google Streetview.
Most recently, Maria Sainz was President and CEO of Cardiokinetix, a medical device company that developed a novel treatment for heart failure. Prior to Cardiokinetix, Ms. Sainz was President and CEO of Concentric Medical where she led the commercialization of the company’s MERCI system and successfully negotiated its sale to Stryker Corporation in 2012. Prior to Concentric, Ms. Sainz held various senior management positions at Boston Scientific Corporation and Guidant Corporation including President of the Cardiac Surgery Group and head of Global Marketing for Vascular Interventions. Ms. Sainz serves as a director of several public and private companies and is an Innovation Team Mentor at the Stanford University Biodesign Program.
Ranked #31 out of 100 top tech investors on Forbes’s 2018 Midas List, Rebecca Lynn is a General Partner at Canvas. She focuses on early-stage venture investments in AI, FinTech, digital health, SaaS, and mobile. Rebecca led Canvas’s investments in Casetext, Figure Eight, Gabi, HealthLoop, Owl, Roofstock, and Vida Health, and currently sits on the boards of each. She also led Canvas’s investment in Luminar, 11 Honore, as well as, FutureAdvisor which was acquired by BlackRock.
Tom Rodgers leads the McKesson Venture Fund, which focuses on helping build businesses that will drive toward a stronger, more sustainable future for the health care industry. Target investments span a broad section of the health care industry with a focus on opportunities created by emerging trends in consumerism, alternative delivery models, shift toward value-based payments, and analytics. Prior to rejoining McKesson, he spent a decade in health care venture capital, most recently leading strategic investing effort for Cambia Health and before that with Advanced Technology Ventures. His investments include Aperio (sold to Danaher), Helixis (sold to Illumina), Zeltiq (Nasdaq: ZLTQ), and more recently Accolade, PipeLineRx, Evariant, Carena, and ClearCare on behalf of McKesson.
Camille Samuels is a Partner at Venrock, a venture capital firm originally established in the late 1960s as the venture arm of the Rockefeller family. Her investment interests span early-stage biotech to medical devices to consumer health. For instance, she serves on the board of directors of Unity biotech (UBX), a public longevity company — and is an observer on the board at Corvidia, a private cardiorenal company. She stepped off the board of RegenXBIO (RGNX) a year after it went public — and from Spirox after its acquisition by Entellus (and Stryker).
VP Strategy
Michele Barry, MD, FACP, FASTMH is Professor of Medicine and Tropical Diseases at Stanford University. She is the Director of the Center for Innovation in Global Health and Senior Associate Dean for Global Health. As one of the co-founders of the Yale/Stanford Johnson and Johnson Global Health Scholar Award program, she has sent over 1500 physicians overseas to underserved areas to help strengthen health infrastructure in low resource settings. As a past President of the American Society of Tropical Medicine and Hygiene (ASTMH), she led an educational initiative in tropical medicine and travelers health which culminated in diploma courses in tropical medicine both in the U.S. and overseas, as well as a U.S. certification exam. Dr. Barry is an elected member of the National Academy of Medicine (NAM) and National Academy of Sciences since 2002. She has been selected for Best Doctors in America and currently sits on the NAM Board on Global Health. She is also the 2018 recipient of AMWA’s highest award – the Elizabeth Blackwell medal for creating pathways for women in medicine.
Dr. Anurag Mairal is an Adjunct Professor of Medicine and the Director, Global Outreach Programs at Stanford Byers Center for Biodesign, Stanford University. He is also an Adjunct Professor at Stanford’s Graduate School of Business and a Faculty Fellow and Lead for Technology Innovation and Impact at Center for Innovation in Global Health. In these roles, he leads initiatives focused on applying the biodesign process to resource-constrained settings globally. Further, he facilitates opportunities for students, faculty and fellows at Stanford to work on global healthcare needs. He is part of the founding faculty team for BIOE 371, Global Biodesign: Medical Technology in an International Context, a graduate-level course offered to engineering, business, and medical students at Stanford University. Earlier, he served as Associate Director for the Stanford-India Biodesign and Singapore-Stanford Biodesign programs. He serves as the Founding Chair of BME IDEA APAC, a community of medtech innovation programs in Asia Pacific, partnering closely with the industry and academia in the region. He is also an Honorary Professor at University of Cape Town, South Africa. Concurrently, he is a co-founder and Executive Vice President of Orbees Medical, a SF Bay Area-based strategy consulting firm serving global healthcare industry, with a focus on medtech, pharmaceutical, and digital health industry. 
Amy Lin is CII’s Acting Deputy Director and Market Access Team Lead, where she focuses on market-based strategies like strategic planning, market shaping and innovative financing to accelerate adoption of high-priority health interventions. Previously, Amy was based in Mumbai with Monitor Inclusive Markets, where she developed social enterprise models that provide clean drinking water in slums. Prior to this role, she served as the HIV/AIDS Program Director for the Clinton Health Access Initiative (CHAI) in Liberia. Before CHAI, Amy was at the World Bank’s Development Marketplace, which funds new approaches to serving the poor.
Daniel Kraft is a Stanford and Harvard trained physician-scientist, inventor, entrepreneur, and innovator. With over 25 years of experience in clinical practice, biomedical research and healthcare innovation, Kraft has served as Faculty Chair for Medicine at 
Mintu P. Turakhia, MD MAS
Praveen Raja, PhD, is Chief Operating Officer at PATH, a major global health NGO. In this role, he is focused on bringing cohesion to the operations functions at PATH to more effectively and efficiently support PATH’s mission of accelerating health equity across the globe. In addition, Dr. Raja also serves as an institutional officer for the organization to guide global business development strategy.
Steve became PATH’s president and CEO in 2012. Before joining PATH, he was director of Social Innovation at McKinsey & Company, CEO of the global digital media firm Corbis, and interim director of the Infectious Disease Research Institute. Prior to that, he practiced law at the international law firm K&L Gates. He has also worked extensively on refugee programs and policies, as well as Chinese politics and law.